Ubs Asset Management Americas Inc Crinetics Pharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $381 Billion
- Q3 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 271,747 shares of CRNX stock, worth $10.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
271,747
Previous 260,980
4.13%
Holding current value
$10.1 Million
Previous $11.7 Million
18.74%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CRNX
# of Institutions
242Shares Held
80.1MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA6.29MShares$235 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$233 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$220 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$185 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$167 Million0.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.01B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...